TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07753603: Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Sponsor: Sling Therapeutics, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 130 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,111,504

Rescue Site Savings

+$2,074,336

Unlock Full NCT07753603 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07753603 Rescue Dossier →